Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Gyre Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 56 | 1 | 59 | +4 |
| Shares | 3.41M | 104 | 8.67M | +5.26M (+154.3%) |
| Value | $23.8M | $725 | $57.1M | +$33.4M (+140.5%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Gyre Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| SC China Holding Ltd | 3,750,299 | $24.7M | 2.06% |
| Octagon Capital Advisors LP | 954,416 | $6.29M | 0.58% |
| Nuveen, LLC | 24,505 | $161.5K | 0.00% |
| Millennium Management LLC | 18,488 | $121.8K | 0.00% |
| Price T Rowe Associates Inc | 15,031 | $100.0K | 0.00% |
| Polymer Capital Management (US) LLC | 11,780 | $77.6K | 0.01% |
| SRS Capital Advisors, Inc. | 246 | $1.62K | 0.00% |
| UMA Financial Services, Inc. | 82 | $541 | 0.00% |
| Bare Financial Services, Inc | 79 | $521 | 0.00% |
| Farther Finance Advisors, LLC | 8 | $53 | 0.00% |
| Rothschild Investment LLC | 1 | $7 | 0.00% |
Sold out (7)
Institutions that held Gyre Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Brevan Howard Capital Management LP | 13,808 | $96.2K |
| Simplex Trading, LLC | 674 | $4.70K |
| Nisa Investment Advisors, LLC | 102 | $711 |
| US Bancorp | 98 | $683 |
| Advisory Services Network, LLC | 66 | $460 |
| Massmutual Trust Co FSB | 12 | $84 |
| MAI Capital Management | 4 | $28 |
Not filed for Q2 2026 yet (1)
Institutions that held Gyre Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| CWM, LLC | 104 | $725 |